Cinitapride

Cinitapride

Cinitapride
Systematic (IUPAC) name
(RS)-4-amino-N-[1-(1-cyclohex-3-enylmethyl)-4-piperidyl]-2-ethoxy-5-nitro-benzamide
Clinical data
Legal status
  • Prescription only
Routes Oral
Identifiers
CAS number  YesY
ATC code None
PubChem
DrugBank
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEMBL
Chemical data
Formula C21H30N4O4 
Mol. mass 402.49 g/mol
 YesY   

Cinitapride (Cintapro, Pemix) is a gastroprokinetic agent and antiulcer agent of the benzamide class which is marketed in India, Mexico, Pakistan and Spain.[1][2] It acts as an agonist of the 5-HT1 and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors.[3][4]

Uses

It is indicated for the treatment of gastrointestinal disorders associated with motility disturbances such as gastroesophageal reflux disease, non-ulcer dyspepsia and delayed gastric emptying.

See also

References

  1. ^ Robert M, Salvà M, Segarra R, et al. (July 2007). "The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole". Drug Metabolism and Disposition: the Biological Fate of Chemicals 35 (7): 1149–56.  
  2. ^ Fernández AG, Massingham R (January 1985). "Peripheral receptor populations involved in the regulation of gastrointestinal motility and the pharmacological actions of metoclopramide-like drugs". Life Sciences 36 (1): 1–14.  
  3. ^ Alarcón-de-la-Lastra Romero C, López A, Martín MJ, la Casa C, Motilva V (April 1997). "Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds". Pharmacology 54 (4): 193–202.  
  4. ^ Alarcón de la Lastra C, La Casa C, Martin MJ, Motilva V (March 1998). "Effects of cinitapride on gastric ulceration and secretion in rats". Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.] 47 (3): 131–6.